SCHEMBL6848486

SCHEMBL6848486

Fc1ccc(-c2c(-c3ccccc3)oc3ncnc(Cl)c23)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TNK2 Q07912 1/20 0.58
ALDH1A1 P00352 3/20 0.51
HPGD P15428 3/20 0.51
KDM4E B2RXH2 2/20 0.51
UBE2N P61088 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TSHR P16473 2/20 0.50
HSD17B10 Q99714 2/20 0.50
AURKA O14965 9/20 0.49
CHEK1 O14757 3/20 0.49
MAP2K1 Q02750 1/20 0.49
EGFR P00533 2/20 0.48
MERTK Q12866 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
MAPK1 P28482 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
RAD52 P43351 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735560 0.92 TNK2 (0.68) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL1790077 0.88 ALDH1A1 (0.45) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL6202986 0.88 ALDH1A1 (0.45) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL1787179 0.86 TNK2 (0.58) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL2977130 0.86 TNK2 (0.58) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL6200319 0.84 ALDH1A1 (0.41) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL2975999 0.83 KDM4E (0.74) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL1785983 0.83 TNK2 (0.54) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL1785974 0.83 KDM4E (0.74) TNK2ALDH1A1HPGDKDM4EUBE2N
SCHEMBL6202574 0.83 TNK2 (0.53) TNK2ALDH1A1HPGDKDM4EUBE2N

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259888-A1 Novel 4-aminofuropyrimidines and the use thereof DPYD, TPMT, TYMP TNK2 2813/4885ALDH1A1 176/4885HPGD 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.